Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists

A compound according to formula (I);

• wherein:
• A is phenyl or pyridyl optionally substituted with L, where L is a moiety selected from trifluoromethyl, nitro, hydroxy, amino, cyano, benzenesulphonamido, aminosulphonyl, oxazolyl, pyridyl, thiazolyl, pyrimidyl, pyrazinyl, pyridazinyl, halo, (C1-C6)alkyl optionally substituted with a group selected from hydroxy, amino, halo, nitro and cyano, (C1-C6)alkoxy, (C1-C4)alkylamino, di(C1-C4)alkylamino, S(O)pCF3 wherein p is 0, 1 or 2, carbamoyl, S(O)p(C1-C6)alkyl, (C1-C4)alkylcarbamoyl, di(C1-C4)alkylcarbamoyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C2-C4)alkenylamino, N-(C2-C4)alkenyl-N-(C1-C4)alkylamino, di-(C2-C4)alkenylamino, S(O)p(C2-C6)alkenyl, (C2-C4)alkenylcarbamoyl, di(C2-C4)alkenylcarbamoyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C3)alkyl, (C3-C7)cycloalkyl(C2-C3)alkenyl, (C5-C7)cycloalkenyl, (C5-C7)cycloalkenyl(C1-C3)alkyl, (C5-C7)cycloalkenyl(C2-C3)alkenyl, (C5-C7)cycloalkenyl(C2-C3)alkynyl, (C1-C4)alkoxycarbonylamino, (C1-C4)alkanoylamino, (C1-C4)alkanoyl(N-(C1-C4)alkyl)amino, (C1-C4)alkanesulphonamido, (C1-C4)alkylaminosulphonyl, di(C1-C4)alkylaminosulphonyl, (C1-C4)alkoxycarbonyl, (C1-C4)alkanoyloxy, (C1-C6)alkanoyl, formyl(C1-C4)alkyl, trifluoro(C1-C3)alkylsulphonyl, hydroxyimino(C1-C6)alkyl, (C1-C4)alkoxyimino(C1-C6)alkyl and (C1-C6)alkylcarbamoylamino;
• B is phenyl;
• D is phenyl optionally substituted with L;
• the —Z—R1 and —X—D groups are positioned in a 1-2 relationship to one another on phenyl or pyridyl ring A;
• the phenyl-ring A atom positioned ortho to the —X— linking group, in the 3-position relative to the —Z— linking group, is not substituted;
• R1 is positioned on the phenyl-ring B in a 1-3 or 1-4 relationship with the —Z— linking group;
• R1 is carboxy;
• Z is selected from —CH(R3a)CH(R3a)N(R2)—, —CH(R3a)N(R2)— and —CH(R3a)S— wherein R3a is selected from (C1-C4)alkyl and the left-most atom of each aforesaid moiety is attached to A;
• or Z is selected from —CH(R3)N(R2)CH(R3)— and —N(R2)CH(R3)— wherein R3 is selected from hydrogen or (C1-C4)alkyl and the left-most atom of each aforesaid moiety is attached to A;
• X is selected from —OCH2—, —CH2CH2— and —N(R2)CH2— wherein the left most atom of each aforesaid moiety is attached to A, and
• R2 is selected from hydrogen, or (C1-C6)alkyl,
• with the proviso that when Z is —CH(R3a)N(R2), X is not —O—CH2—;
• N-oxides of —NR2, where chemically possible;
• S-oxides of sulphur-containing rings where chemically possible;
• or pharmaceutically-acceptable salts or in vivo-hydrolysable esters thereof.